The Cost of Stroke to the National Health Service in Scotland

Isard, Phoebe A.; Forbes, John F.

doi:10.1159/000108988

Cited by 106 publications

(51 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 It remains the most common cause of disability in adults. Effective acute treatments are proving elusive, and so prevention of stroke is crucial.…”

Section: The Burden Of Strokementioning

confidence: 99%

“…echocardiogram, various blood tests) in the evaluation of patients with TIA and minor stroke for secondary stroke prevention, using local Edinburgh estimates of cost, but this only considered US and IAA, as at that time CTA and MRA were really only experimental. Their recommendations were that the most cost-effective strategy for selecting patients for IAA before endarterectomy, was to (1) ensure that the patient has carotid territory TIAs/minor stroke, (2) ensure that the patient was medically fit and willing to consider carotid IAA and endarterectomy, and (3) perform carotid US before considering IAA. If the US suggested more than about 50% diameter symptomatic internal carotid artery stenosis, then the patient should be considered for IAA.…”

Section: Improving the Assessment Of Diagnostic Testsmentioning

confidence: 99%

See 1 more Smart Citation

Accurate, practical and cost-effective assessment of carotid stenosis in the UK

Wardlaw

Chappell²,

Stevenson³

et al. 2006

Health Technol Assess

139

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

“…1 It remains the most common cause of disability in adults. Effective acute treatments are proving elusive, and so prevention of stroke is crucial.…”

Section: The Burden Of Strokementioning

confidence: 99%

Section: Improving the Assessment Of Diagnostic Testsmentioning

confidence: 99%

Accurate, practical and cost-effective assessment of carotid stenosis in the UK

Wardlaw

Chappell²,

Stevenson³

et al. 2006

Health Technol Assess

139

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] The majority of these costs and resources are related to hospital inpatient services, with an estimated 80% of stroke patients being admitted to the hospital in inner-city districts. 5 Once admitted, a study of 9 hospitals in 6 European states demonstrated that stroke patients have long lengths of stay relative to other acute conditions.…”

mentioning

confidence: 99%

Economic Consequences of Early Inpatient Discharge to Community-Based Rehabilitation for Stroke in an Inner-London Teaching Hospital

Beech

Rudd

Tilling

et al. 1999

Stroke

109

View full text Add to dashboard Cite

Background and Purpose-In an inner-London teaching hospital, a randomized trial of "conventional" care versus early discharge to community-based therapy found no significant differences in clinical outcomes between patient groups. This report examines the economic consequences of the alternative strategies. Methods-One hundred sixty-seven patients received the early discharge package, and 164 received conventional care.Patient utilization of health and social services was recorded over a 12-month period, and cost was determined using data from provider departments and other published sources. Results-Inpatient stay after randomization was 12 days (intervention group) versus 18 days (controls) (Pϭ0.0001).Average units of therapy per patient were as follows: physiotherapy, 22.

show abstract

“…Per-patient costs of stroke in the European Union (EU) have recently been estimated using time horizons from 6 months to the patient's lifetime. [5][6][7][8][9][10][11] Lifetime direct costs of stroke (1996) estimated from a model with two randomized trials of stroke treatment conducted in 13 countries were $82 000. 12 The incidence and costs of stroke are expected to increase substantially as the population of industrialized countries ages in the coming decades.…”

Section: Introductionmentioning

confidence: 99%

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Dahlöf

Krobot

et al. 2004

J Hum Hypertens

View full text Add to dashboard Cite

The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study was designed to compare losartan-vs atenolol-based antihypertensive treatment on cardiovascular morbidity and mortality in a population of 9193 hypertensive patients with left ventricular hypertrophy (LVH). In LIFE, the losartan-based treatment further reduced the primary composite end point (cardiovascular death, myocardial infarction, or stroke) by 13% (risk reduction (RR) 0.87, 95% confidence interval (CI) 0.77-0.98, P ¼ 0.021). The further reduction in stroke with losartan (RR 0.75, 95% CI 0.63-0.89, P ¼ 0.001) was the major contributing factor to the reduction in the primary end point. Our objective was to project the reduction in stroke observed with a losartan-vs an atenolol-based antihypertensive treatment regimen in the LIFE study to the European Union (EU) population. The number of stroke events averted was estimated by identifying the number of persons in the EU expected to meet the LIFE inclusion criteria, and multiplying this figure by the cumulative incidence risk difference in stroke from LIFE at 5.5 years. The age-and gender-specific prevalence of hypertension, electrocardiographically (ECG)-diagnosed LVH among those with hypertension (inclusion criteria), and heart failure among those with LVH and hypertension (exclusion criteria) were applied to the EU census estimates. We conservatively projected that an estimated 7.8 million individuals aged 55-80 years in the EU are affected by hypertension and ECG-diagnosed LVH. Use of a losartan-based antihypertensive treatment in this population is projected to prevent approximately 125 000 first strokes over a 5.5-year period. A population-wide prevention strategy of using losartan in patients with LVH and hypertension has the potential to have a major public health impact by reducing the morbidity and mortality of stroke in the EU.

show abstract

The Cost of Stroke to the National Health Service in Scotland

Cited by 106 publications

References 11 publications

Accurate, practical and cost-effective assessment of carotid stenosis in the UK

Accurate, practical and cost-effective assessment of carotid stenosis in the UK

Economic Consequences of Early Inpatient Discharge to Community-Based Rehabilitation for Stroke in an Inner-London Teaching Hospital

Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

Contact Info

Product

Resources

About